Skip to main content

Single Invitation for PSA Screening Cuts Prostate Cancer Deaths

Medically reviewed by Carmen Pope, BPharm. Last updated on April 8, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, April 8, 2024 -- A single invitation for prostate-specific antigen (PSA) screening is associated with reduced prostate cancer deaths, although the absolute reduction is small, according to a study published online April 6 in the Journal of the American Medical Association to coincide with the 39th Annual European Association of Urology Congress, held from April 5 to 8 in Paris.

Richard M. Martin, B.M., B.S., Ph.D., from the University of Bristol in the United Kingdom, and colleagues examined the effect of a single invitation for PSA screening on prostate cancer-specific mortality in a secondary analysis of the Cluster Randomized Trial of PSA Testing for Prostate Cancer involving men aged 50 to 69 years. Ninety-eight percent of the 415,357 eligible men were included in the analyses.

In the intervention and control groups, 12,013 and 12,958 men had a prostate cancer diagnosis (15-year cumulative risk, 7.08 and 6.94 percent, respectively). The researchers found that 0.69 and 0.78 percent of men in the intervention and control groups, respectively, died of prostate cancer at a median 15-year follow-up (rate ratio, 0.92). The PSA screening intervention increased detection of low-grade and localized disease compared with control. All-cause deaths did not differ significantly between the groups (23.2 and 23.3 percent in the intervention and control groups, respectively). Overall, 0.7 and 0.5 percent of prostate cancer deaths in the intervention and control groups, respectively, were related to a diagnostic biopsy or prostate cancer treatment.

"Policymakers considering screening for prostate cancer should consider this small reduction in deaths against the potential adverse effects associated with overdiagnosis and overtreatment of prostate cancer," the authors write.

Two authors disclosed ties to industry.

Abstract/Full Text

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

ACG: 2000 to 2022 Saw Rise in Early-Onset CRC Mortality in the United States

THURSDAY, Oct. 31, 2024 -- Early-onset colorectal cancer (EO-CRC) mortality rose in the United States over the past two decades, most notably in patients aged 20 to 44 years...

Cell-Free Blood DNA Tests Less Effective Than Other CRC Screening

WEDNESDAY, Oct. 30, 2024 -- Cell-free DNA blood tests (cf-bDNA) may be more costly and less effective for colorectal cancer (CRC) screening than other screening modalities...

American College of Surgeons, Oct. 19-22

The annual meeting of the American College of Surgeons was held this year from Oct. 19 to 22 in San Francisco and attracted participants from around the world, including...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.